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Background
It is uncertain whether aspirin therapy should be con-
tinued after endoscopic hemostatic therapy in patients 
who develop peptic ulcer bleeding while receiving low-
dose aspirin.
Objective
To test that continuing aspirin therapy with proton-
pump inhibitors after endoscopic control of ulcer bleed-
ing was not inferior to stopping aspirin therapy, in terms 
of recurrent ulcer bleeding in adults with cardiovascular 
or cerebrovascular diseases.
Design
A parallel randomized, placebo-controlled noninferiority 
trial, in which both patients and clinicians were blinded to 
treatment assignment, was conducted from 2003 to 2006 by 
using computer-generated numbers in concealed envelopes. 
(ClinicalTrials.gov registration number: NCT00153725)
Setting
A tertiary endoscopy center.
Patients
Low-dose aspirin recipients with peptic ulcer bleeding.
Intervention
78 patients received aspirin, 80 mg/d, and 78 received 
placebo for 8 weeks immediately after endoscopic 
therapy. All patients received a 72-hour infusion of 
pantoprazole followed by oral pantoprazole. All patients 
completed follow-up.
Measurements
Th e primary end point was recurrent ulcer bleeding 
within 30 days conﬁ rmed by endoscopy. Secondary end 
points were all-cause and cause-speciﬁ c mortality in 
8 weeks.
Results
156 patients were included in an intention-to-treat 
analysis. Th ree patients withdrew from the trial before 
ﬁ nishing follow-up. Recurrent ulcer bleeding within 
30 days was 10.3% in the aspirin group and 5.4% in the 
placebo group (diﬀ erence, 4.9 percentage points [95% CI, 
−3.6 to 13.4 percentage points]). Patients who received 
aspirin had lower all-cause mortality rates than patients 
who received placebo (1.3% vs. 12.9%; diﬀ erence, 11.6 
percentage points [CI, 3.7 to 19.5 percentage points]). 
Patients in the aspirin group had lower mortality rates 
attributable to cardiovascular, cerebrovascular, or 
gastrointestinal complications than patients in the 
placebo group (1.3% vs. 10.3%; diﬀ erence, 9 percentage 
points [CI, 1.7 to 16.3 percentage points]).
Limitations
Th e sample size is relatively small, and only low-dose 
aspirin, 80 mg, was used. Two patients with recurrent 
bleeding in the placebo group did not have further 
endoscopy.
Conclusion
Among low-dose aspirin recipients who had peptic ulcer 
bleeding, continuous aspirin therapy may increase the 
risk for recurrent bleeding but potentially reduces 
mortality rates. Larger trials are needed to conﬁ rm these 
ﬁ ndings.
Commentary
Fifty million Americans use low-dose aspirin, 325mg/day 
or less, regularly for cardioprophylaxis1. Th e estimated © 2010 BioMed Central Ltd
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average excess risk of upper gastrointestinal bleeding 
(UGIB) related to cardioprophylactic doses of ASA is 5 
cases per 1000 ASA users per year 2. Currently the 2010 
International Consensus on Non-variceal Upper Gastro-
intestinal Bleeding is that - In patients who receive low-
dose ASA and develop acute ulcer bleeding, ASA therapy 
should be restarted as soon as the risk for cardiovascular 
complication is thought to outweigh the risk for bleeding.3 
One signiﬁ cant problem with this recommendation is 
that the risks of when one outweighs the other is very ill 
deﬁ ned. It has been shown that prolonged discon tinu-
ation of ASA therapy increases thrombotic risk 4. Th is 
creates a conundrum for physicians trying to balance the 
risk of re-bleed vs. cardiac or cerebrovascular event risk.
Th e purpose of this study was to determine that 
restarting ASA therapy after endoscopic control of the 
UGIB was not inferior to stopping ASA therapy. It was a 
randomized placebo non-inferiority study where patients 
were randomly assigned to placebo or ASA therapy after 
endoscopic control of an UGIB. Th e primary outcome 
was to evaluate the occurrence of recurrent peptic ulcer 
bleed within 30 days of the initial event. Secondary 
outcomes included all cause mortality, and death 
attributed to cardiovascular, cerebrovascular or gastro-
intestinal complications. Secondary endpoints included 
blood transfusion requirement, duration of hospital stay, 
requirement of surgery, and recurrence of acute ischemic 
events (ACS/CVA). Th ere was no signiﬁ cant diﬀ erence in 
the primary outcome measure, incidence of recurrent 
ulcer bleeding at 30 days (10.3% in the low-dose aspirin 
group and 5.4% in the placebo group, diﬀ erence 4.9 
percentage points, [CI -3.6 to 13.4 percentage points]). 
All cause mortality was lower in the ASA group (1.3% in 
the ASA group at 56 days and 12.9% in the placebo group, 
diﬀ erence of 11.6 percentage points, [CI 3.7 to 19.5 
percentage points]). Th ere was no diﬀ erence between the 
two groups regarding the other secondary outcomes.
Th e strength of this paper is that it was a well designed 
study. Th e patients were well randomized and the 
evaluators were blinded to the treatment groups. 
Limitations include a small sample size and concerns as 
to whether the information can be extrapolated to 
patients that use higher doses of ASA. In addition, there 
were 2 patients in the placebo group that did not undergo 
endoscopy -1 died before getting to the hospital, and the 
other patient was too unstable for recurrent endoscopy. 
Th ese two patients were not added to the primary 
analyses. If they were added to the cases of recurrent 
bleeding the diﬀ erence between the two groups would be 
reduced.
Th e ﬁ ndings of this study suggest that early resumption 
of ASA has a trade-oﬀ . While early resumption increased 
risk of re-bleeding, it reduced risk of subsequent 
cardiovascular events. Th is study used a single primary 
endpoint and non-inferiority margin of 10%, i.e. the trial 
had adequate power to detect a >10% higher risk of re-
bleeding in the group where ASA was resumed imme-
diately. For instance, the re-bleeding risk in the group 
where ASA was resumed immediately was 4.9% higher 
compared to the group in whom ASA was resumed later. 
Th is diﬀ erence was not statistically signiﬁ cant, but the 
study was underpowered to detect such small diﬀ erences. 
Th ese ﬁ ndings raise questions regarding the optimal 
design of trials to address this issue. Is the 10% non-
inferiority margin acceptable and should the authors 
have designed a study to detect smaller diﬀ erences in re-
bleeding risk? Similar to prior studies,5 one approach 
would be to use a non-inferiority design to compare 
bleeding risk and superiority design to compare all-cause 
mortality.
Th e results of this study need to be conﬁ rmed in a 
larger study as its treatment implications for all health 
providers could be great in terms of managing their 
patients after UGI bleeds. Like any good study, it raises 
several additional questions: What is the appropriate 
dose of ASA that should be restarted? What is the 
appropriate time interval from endoscopy until ASA 
resumption?
Recommendation
In conclusion, patients that have an UGIB that need 
cardioprophylaxis or cerebrovascular prophylaxis should 
be restarted on their ASA therapy as soon as endoscopic 
control of their UGIB source has been controlled.
Competing interests
The authors declare that they have no competing interests.
Published: 20 December 2010
References
1.  Chan FK, Graham DY: Prevention of non-steroidal anti-infl ammatory drug 
gastrointestinal complications – review and recommendations based on 
risk assessment. Aliment Pharmacol Ther 2004, 19:1051-61.
2.  Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M, Rawlins M, 
Vessey M, Wainwright P: Prophylactic aspirin and risk of peptic ulcer 
bleeding. BMJ 1995, 310:827-30.
3.  Barkun AN, Bardou M, Kuipers EJ, Sung J, Hunt RH, Martel M, Sinclair P; 
International Consensus Upper Gastrointestinal Bleeding Conference Group: 
International consensus recommendations on the management of 
patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 
2010, 152:101-113.
4.  Aguejouf O, Eizayaga F, Desplat V, Belon P, Doutremepuich C: Prothrombotic 
and hemorrhagic eff ects of aspirin. Clin Appl Thromb Hemost 2009, 15:523-8.
5. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, Schortgen F, 
Lasocki S, Veber B, Dehoux M, Bernard M, Pasquet B, Régnier B, Brun-Buisson 
C, Chastre J, Wolff  M; PRORATA trial group: Use of procalcitonin to reduce 
patients’ exposure to antibiotics in intensive care units (PRORATA trial): a 
multicentre randomized controlled trial. Lancet 2010, 375:463-474.
doi:10.1186/cc9368
Cite this article as: Gooch R, Baldisseri M: How soon to start: aspirin 
resumption after upper gastrointestinal bleed? Critical Care 2010, 14:331.
Gooch and Baldisseri Critical Care 2010, 14:331 
http://ccforum.com/content/14/6/331
Page 2 of 2
